title: Antivascular agents for non-small-cell lung cancer: current status and future directions.
abstract: BACKGROUND
  Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs.
  
  
  OBJECTIVE
  To summarize the current knowledge on antivascular therapy in patients with NSCLC.
  
  
  METHODS
  Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs.
  
  
  CONCLUSIONS
  Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC.
authors.affiliation: Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, UK.
authors.forename: Eitan
authors.initials: E
authors.lastname: Amir
authors.forename: Laszlo
authors.initials: L
authors.lastname: Mandoky
authors.forename: Fiona
authors.initials: F
authors.lastname: Blackhall
authors.forename: Nick
authors.initials: N
authors.lastname: Thatcher
authors.forename: Walter
authors.initials: W
authors.lastname: Klepetko
authors.forename: Hendrik Jan
authors.initials: HJ
authors.lastname: Ankersmit
authors.forename: Mir Ali
authors.initials: MA
authors.lastname: Reza Hoda
authors.forename: Gyula
authors.initials: G
authors.lastname: Ostoros
authors.forename: Magdolna
authors.initials: M
authors.lastname: Dank
authors.forename: Balazs
authors.initials: B
authors.lastname: Dome
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor